Pique Therapeutics, based in Durham, NC, is a biotechnology company seeking to become the leading therapeutic vaccine company, focused initially on the treatment of cancer. Pique’s lead product is a first-in-class therapeutic vaccine (PT 107) for the treatment of non-small cell lung cancer (NSCLC). PT 107 has completed Phase 1 clinical trials, was well-tolerated, and had an excellent safety profile in cancer patients. PT 107 showed a 134% improvement in median survival (11 months) for patients with late-stage NSCLC, as compared with the expected 4 to 6 months. Remarkably, almost 25% of the patients are still alive and in remission after 3 years. PT 107 is currently in a two-arm, double-blind Phase 2 study, to further examine the safety and efficacy of the drug.